State Street Corp Has $21.59 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

State Street Corp grew its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,945,060 shares of the biotechnology company’s stock after buying an additional 64,949 shares during the quarter. State Street Corp owned 2.06% of Aurinia Pharmaceuticals worth $21,587,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC lifted its position in Aurinia Pharmaceuticals by 4,307.9% in the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after acquiring an additional 535,301 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the third quarter valued at about $3,330,000. Stonepine Capital Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $1,713,000. AQR Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $1,155,000. Finally, PDT Partners LLC raised its position in Aurinia Pharmaceuticals by 76.0% in the 3rd quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after buying an additional 130,204 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Down 0.9 %

NASDAQ:AUPH opened at $8.95 on Tuesday. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -59.66 and a beta of 1.41. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $8.31 and its two-hundred day moving average price is $6.92.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the sale, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.